Mosby's 2014 Nursing Drug Reference (385 page)

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

HIGH ALERT
tenecteplase (TNK-tPA)(Rx)

(ten-ek′ta-place)

TNKase

Func. class.:
Thrombolytic

Chem. class.:
Tissue plasminogen activator

ACTION:

Activates conversion of plasminogen to plasmin (fibrinolysin): plasmin breaks down clots (fibrin), fibrinogen, factors V, VII; occlusion of venous access lines

USES:

Acute myocardial infarction, coronary artery thrombosis

CONTRAINDICATIONS:

Hypersensitivity, arteriovenous malformation, aneurysm, active bleeding, intracranial/intraspinal surgery or trauma within 2 mo, CNS neoplasms, severe hypertension, severe renal/hepatic disease, history of CVA, increased ICP/stroke

Precautions:
Pregnancy (C), breastfeeding, children, geriatric patients, arterial emboli from left side of heart, hypocoagulation, subacute bacterial endocarditis, rheumatic valvular disease, cerebral embolism/thrombosis/hemorrhage, intraarterial diagnostic procedure or surgery (10 days), recent major surgery, dysrhythmias, hypertension

DOSAGE AND ROUTES
Calculator
Total dose, max 50 mg based on patient’s weight

• Adult <60 kg:
IV BOL
30 mg, give over 5 sec

• Adult ≥60-<70 kg:
IV BOL
35 mg, give over 5 sec

• Adult ≥70-<80 kg:
IV BOL
40 mg, give over 5 sec

• Adult ≥80-<90 kg:
IV BOL
45 mg, give over 5 sec

• Adult ≥90 kg:
IV BOL
50 mg, give over 5 sec, max 50 mg total dose

Available forms:
Powder for inj, lyophilized 50 mg

Administer:
Intermittent IV INF route

• 
As soon as thrombi identified; not useful for thrombi >1 wk old

• 
Cryoprecipitate or fresh frozen plasma if bleeding occurs

• 
Heparin after fibrinogen level >100 mg/dl; heparin inf to increase PTT to 1.5-2× baseline for 3-7 days; IV heparin with loading dose is recommended

• 
Aseptically withdraw 10 ml of sterile water for inj from diluent vial, use red cannula syringe-filling device, inject all contents of syringe into product vial, direct into powder, swirl, withdraw correct dose, discard any unused sol; stand shield with dose vertically on flat surface and passively recap red cannula, remove entire shield assembly by twisting counter-clockwise, give by IV BOL

• 
IV therapy: use upper-extremity vessel that is accessible to manual compression

• 
If product not used immediately, refrigerate, use within 8 hr; not compatible with dextrose; flush dextrose-containing lines with saline before and after administration

SIDE EFFECTS

CV:
Dysrhythmias, hypotension, pulmonary edema,
pulmonary embolism, cardiogenic shock, cardiac arrest, heart failure, myocardial reinfarction, myocardial rupture, tamponade, pericarditis, pericardial effusion, thrombosis, CVA

HEMA:
Decreased Hct,
bleeding

INTEG:
Rash, urticaria, phlebitis at IV inf site, itching, flushing

SYST:
GI, GU, intracranial, retroperitoneal bleeding, surface bleeding, anaphylaxis

PHARMACOKINETICS

IV:
Onset immediate, half-life 20-24 min, metabolized by liver

INTERACTIONS

Increase:
bleeding—aspirin, indomethacin, phenylbutazone, anticoagulants, antithrombolytics, glycoprotein IIb/IIIa inhibitors, dipyridamole, clopidogrel, ticlopidine, NSAIDs, cefamandole, cefoperazone, cefoTEtan, SSRIs, SNRIs

Drug/Herb

Increase:
risk of bleeding—feverfew, garlic, ginger, ginkgo, green tea, horse chestnut

Drug/Lab Test

Increase:
INR, PT, PTT

NURSING CONSIDERATIONS
Assess:

• 
Allergy:
fever, rash, itching, chills; mild reaction may be treated with antihistamines

• 
Cholesterol embolism, blue-toe syndrome, renal failure, MI, cerebral/spinal cord/bowel/retinal infarction, hypertension; can be fatal

 
Bleeding
during 1st hr of treatment; hematuria, hematemesis, bleeding from mucous membranes, epistaxis, ecchymosis; may require tranfusion (rare), continue to assess for bleeding for 24 hr

• 
Blood studies (Hct, platelets, PTT, PT, TT, aPTT) before starting therapy; PT or aPTT must be <2× control before starting therapy; PTT or PT q3-4hr during treatment

• 
Hypersensitive reactions: fever, rash, dyspnea; product should be discontinued

• 
VS, B/P, pulse, respirations, neurologic signs, temp at least q4hr; temp >104° F (40° C) indicates internal bleeding; systolic pressure increase >25 mm Hg should be reported to prescriber

 
Neurologic changes that may indicate intracranial bleeding

 
Retroperitoneal bleeding: back pain, leg weakness, diminished pulses

Perform/provide:

• 
Bed rest during entire course of treatment

• 
Avoidance of venous or arterial puncture, inj, rectal temp, any invasive treatment

• 
Treatment of fever with acetaminophen or aspirin

• 
Pressure for 30 sec to minor bleeding sites; inform prescriber if this does not attain hemostasis; apply pressure dressing

Evaluate:

• 
Therapeutic response: resolution of MI

Teach patient/family:

• 
About proper dental care to avoid bleeding

• 
To notify prescriber immediately of sudden, severe headache

• 
To notify prescriber of bleeding; hypersensitivity; fast, slow, or uneven heart rate; feeling of faintness; blood in urine, stools; nose bleeds

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

Other books

Heaven Is High by Kate Wilhelm
Urban Outlaws by Peter Jay Black
Being There by T.K. Rapp
Relinquishing Liberty by Mayer, Maureen
Eitana, la esclava judía by Javier Arias Artacho
Exposure by Helen Dunmore
On Pointe by Sheryl Berk
Lluvia negra by Graham Brown